Opendata, web and dolomites

NeoCellBank

A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NeoCellBank project word cloud

Explore the words cloud of the NeoCellBank project. It provides you a very rough idea of what is the project "NeoCellBank" about.

people    animals    unrestricted    estimating    tissue    context    pay    adult    endogenous    burden    diseases    revolutionize    accelerator    invasive    economic    anti    reverse    shared    source    euros    chronic    expensive    mature    multiple    lower    mainly    humans    disrupt    sedentary    million    mostly    industrialization    lifestyle    human    status    palliative    allogeneic    investment    hire    regeneration    accessible    nsaids    earn    cell    oa    market    regenerative    hold    good    rely    stage    20    pro    alternative    foresee    symptoms    therapies    limited    reaching    finalise    lengthy    solution    26    cells    donor    pharmacological    age    profits    underlying    stem    involve    limits    return    effort    treatments    neonatal    material    biological    off    osteoarthritis    advantages    inflammatory    altered    stronger    appears    pathology    19    incidence    overcome    abundant    recipients    pets    ageing    autologous    society    commercial    experiencing    joint    introducing    amplification    incurring    solutions    completion    therapy    mechanism    vetbiobank    15    medicine    profile    inflammation    immunogenicity    disability    individual    veterinary   

Project "NeoCellBank" data sheet

The following table provides information about the project.

Coordinator
VETBIOBANK SAS 

Organization address
address: 1 AVENUE BOURGELAT
city: MARCY-L'ETOILE
postcode: 69280
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.vetbiobank.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VETBIOBANK SAS FR (MARCY-L'ETOILE) coordinator 50˙000.00

Map

 Project objective

Society is experiencing a rise in chronic inflammatory diseases, mostly due to ageing, and sedentary lifestyle. Osteoarthritis (OA) is one of the leading inflammatory diseases, affecting both humans (incidence 15%) and pets (20%), incurring disability and large economic burden. Current pharmacological treatments for OA involve palliative therapies (NSAIDs) that work on the symptoms, becoming lengthy and expensive with multiple side effects. In this context, regenerative medicine based on stem cells appears as a good alternative, as they reverse the pro-inflammatory status of the joint and promote endogenous tissue regeneration. However, current solutions for OA mainly rely on autologous adult stem cells, obtained through invasive procedures and which hold biological properties altered by donor age and underlying inflammation. Allogeneic adult cells could be used in any individual, but a limited amplification potential limits the number of recipients. In response, we aim to revolutionize the field of regenerative medicine by introducing a unique cell therapy based on neonatal stem cells. These cells have many advantages over adult cells: source material is accessible & abundant, cells show stronger anti-inflammatory properties, and lower immunogenicity profile which allows for unrestricted allogeneic use. The main goal of our project is to finalise industrialization and bring to market our reliable cell-based solution for OA. In Phase 1 we will define the technical and commercial steps to overcome before reaching mature stage. Upon completion of this project, we foresee our product to disrupt the veterinary market of inflammatory diseases. Moreover, since the pathology mechanism for OA is shared between animals and humans, our product could work as an accelerator for human applications. Importantly, the effort will pay off for Vetbiobank, estimating to earn €26 million profits, hire 19 people and reach a Return of Investment of 4.2 Euros after 5 years in the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOCELLBANK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOCELLBANK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

COPI (2020)

Carbon Offset Plug-in

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More